The State of Healthcare Marketing and Compliance: Q2 2026

How fast is healthcare and wellness marketing changing? This is the Q2 2026 edition of Authoritize’s quarterly report on FDA and FTC enforcement and the search market, covering the trailing 12 months. In that window, regulators brought 204 tracked enforcement actions across 11 clinical verticals, up +204.5% from 67 the year before, drawn from an Authoritize Atlas corpus of 745 published FDA and FTC actions. At the same time, when prospective patients ask AI assistants where to get care, the engines name a specific provider in 30% of answers, and the names they give are mostly national brands, not local clinics.

Key findings

• Tracked healthcare-marketing enforcement reached 204 actions in the past 12 months, up +204.5% from 67.
• Across 12 clinical verticals, AI assistants named a specific provider in 30% of buyer questions.
• Patients run 1.6 million buyer-intent searches a month across the tracked verticals.
• Unsubstantiated efficacy claims is the most common violation, flagged 1,282 times.
• Tracked enforcement carried $499.2 million in monetary penalties.

Enforcement by vertical (trailing 12 months)

Vertical	Tracked total	Last 12 months	Prior 12 months	Change
Nutrition / Supplements	380	30	22	+36.4%
Pharmacy / Compounding	121	47	14	+235.7%
GLP-1 / Weight Loss	99	82	11	+645.5%
Medical Spa / Aesthetics	38	19	3	+533.3%
Stem Cell / Regenerative	35	8	12	-33.3%
Functional Medicine	32	4	1	+300%
TRT	13	5	1	+400%
Telehealth Psych	10	2	0	n/a
Peptide	9	5	1	+400%
Longevity	7	2	2	0%
IV / Vitamin	1	0	0	n/a

The table above is the risk map: where regulators are looking, and how fast that attention is growing. But enforcement is only half of what decides whether a clinic gets found. The other half is the search market, where patients actually look for care and where AI assistants decide which providers to name. The two are linked: the verticals drawing the heaviest enforcement are often the same ones with the heaviest patient demand, so the highest-opportunity categories and the highest-risk categories are frequently the same categories. The table below maps those same verticals against monthly search demand, how hard their terms are to rank for, and how often an AI answer names a specific provider at all.

The search market by vertical

Vertical	Monthly searches	Keyword difficulty	AI names a provider	Who wins the AI answer
Medical Spa / Aesthetics	514,514	13	13%	LaserAway, Restore Hyper Wellness
IV / Vitamin	327,700	28	0%	n/a
GLP-1 / Weight Loss	229,593	18	100%	Ro, Noom, Found
Nutrition / Supplements	181,700	50	0%	n/a
Pharmacy / Compounding	99,210	20	0%	n/a
Direct Primary Care	67,790	19	0%	n/a
Peptide	62,413	8	53%	Defy Medical, Marek Health, Peter MD
Longevity	34,081	24	0%	n/a
TRT	32,835	26	93%	Defy Medical, Hims, Hone Health
Functional Medicine	28,887	30	0%	n/a
Telehealth Psych	28,033	39	0%	n/a
Stem Cell / Regenerative	5,781	6	0%	n/a

Enforcement Is Accelerating, and the Stakes Have Never Been Higher

Tracked healthcare-marketing enforcement reached 204 actions in the trailing 12 months, up +204.5% from 67 actions in the prior period. That is not a gradual drift. It is a structural shift in how aggressively federal regulators are moving against marketing claims in healthcare and wellness.

The Authoritize Atlas now holds 745 total published actions across 11 clinical verticals, stretching back to 1995. The trailing-12-month window accounts for a significant share of that entire corpus, which tells you something about the current pace. Clinics that built their marketing on claim language that went unchallenged two or three years ago are now operating in a materially different environment.

The distribution of those 204 actions is uneven, and the pattern matters. GLP-1 / Weight Loss drew 82 actions, making it the single hottest enforcement area in the tracked period. Pharmacy / Compounding followed with 47. Nutrition / Supplements logged 30. Medical Spa / Aesthetics saw 19. Stem Cell / Regenerative recorded 8. TRT and Peptides each showed 5. Functional Medicine logged 4. Telehealth Psych and Longevity each registered 2. IV / Vitamin recorded 0 actions in the trailing 12 months.

That last number deserves a note of its own: zero tracked actions does not mean zero risk. It means the Atlas did not capture a qualifying enforcement action in that vertical during this window. Regulatory attention can shift quickly, and the GLP-1 space was relatively quiet before it wasn’t.

Across those 204 actions, total monetary penalties reached $499.2 million, with a single action accounting for $150 million of that figure. The concentration matters. One enforcement outcome against one company was larger than many clinics’ entire revenue over their operating lifetime. For smaller practices, the exposure is existential, not just financial.

---

The Most Common Violation: Unsubstantiated Efficacy Claims

The most common violation across the Atlas corpus is Unsubstantiated efficacy claims, flagged 1,282 times. That category spans the full range of claim types: outcome promises, before-and-after implications, condition-specific treatment claims, and comparative superiority statements that lack the evidence base to support them.

The 1,282 figure is not a measure of 1,282 separate companies. Enforcement actions frequently cite multiple violations, and a single warning letter can generate several flags. But the volume does tell you that unsubstantiated efficacy language is not an edge case. It is the central, recurring failure mode in healthcare marketing.

The practical read: any claim on a clinic’s website, social feed, or ad copy that asserts or implies a specific health outcome is the category most likely to attract a warning letter or civil penalty. The claim does not need to be dramatic to qualify. Phrases that frame a service as producing a specific result, without disclosed and adequate substantiation, fall squarely in this category.

This matters for marketing strategy as much as for compliance. Content built around mechanistic education, patient eligibility, and process transparency uses fundamentally different language than outcome-claim content. That difference is also the difference between content that accumulates authority over time and content that creates legal exposure.

---

1.6 Million Monthly Searches, and National Brands Are Capturing Most of the Head Terms

Patients run 1.6 million buyer-intent searches a month across the tracked verticals. These are not informational queries. They are searches where the patient is weighing options and moving toward a decision. That is a large, commercially active audience, and most of it flows to search results pages where national telehealth and direct-to-consumer brands have significant structural advantages.

The brands occupying national head-term rankings are built for exactly that competition. They carry domain authority accumulated over years, paid-search budgets that individual clinics cannot match, and content operations running at scale. A single-location or regional clinic competing for terms like “weight loss treatment” or “testosterone therapy online” is bidding against infrastructure, not just other websites.

That is not a reason to give up on search. It is a reason to be precise about where the competition is actually winnable.

National brands are largely absent from local-intent and condition-specific queries. A search that includes a city, a neighborhood, a specific protocol, or a patient’s particular situation is a different competitive environment. Those searches have lower volume individually, but aggregated across a clinic’s full local footprint, they represent real, reachable patient traffic. The 1.6 million monthly figure captures broad national volume. Local and specific queries carve out distinct segments within it, and those segments are not where the national platforms focus their resources.

This series will continue tracking vertical-by-vertical search demand each quarter to show where that volume shifts over time.

---

AI Assistants Are Routing Patients, and the Incumbents Are National Platforms

Across 132 AI answers analyzed across 12 clinical verticals, AI assistants named a specific provider in 30% of responses to buyer-intent questions. That 30% is not evenly distributed. In several verticals, AI answers consistently name the same national platforms. In others, AI answers name no one at all.

Where providers are named, the list is almost entirely national telehealth and direct-to-consumer companies. In GLP-1 / Weight Loss, the providers appearing in AI answers include Ro, Noom, Found, and Weight Watchers. In TRT, the named providers are Defy Medical, Hims, Hone Health, and Maximus. In Peptides, the AI answers surface Defy Medical, Marek Health, and Peter MD. In Medical Spa / Aesthetics, LaserAway and Restore Hyper Wellness appear as named providers.

These are the incumbents a local clinic is measured against when a patient asks an AI assistant for a recommendation. The platforms named above have earned those citations through a combination of content volume, domain authority, structured data, and the kind of specific, consistent published information that AI systems draw on when constructing answers.

The more consequential number for local clinics may be the 70 out of 132 answers that did not name anyone. In verticals where AI answers are still generic, the citation position is not locked up. The practice that builds a documented, specific, accurate, physician-reviewed content record in that vertical has a real opportunity to earn citation before the field closes. This series will track which verticals move from unnamed to named as AI search matures.

The local angle compounds this. Even in verticals where national platforms are currently named for broad questions, local and geographically specific queries often return generic answers. An AI asked “what should I know about medical spa treatments in Phoenix” is drawing on different source material than one asked about national providers. That local content space is where a clinic with genuine local expertise and consistent publishing can realistically compete.

---

The Compliance and Visibility Problem Are the Same Problem

The enforcement data and the visibility data are usually discussed separately. They should not be.

The 1,282 instances of Unsubstantiated efficacy claims flagged across the Atlas represent exactly the kind of language that dominates poorly built health-marketing content: aggressive outcome promises, condition-specific treatment claims, and superlatives without a substantiation basis. That language might generate short-term click volume. It does not build authority, and it does not earn AI citations.

What earns citations in both search and AI answers is specific, accurate, well-sourced content about how a treatment works, who is a candidate, what the clinical process looks like, and what outcomes are supported by published evidence. A physician-reviewed page explaining the physiology of a peptide protocol, the candidacy criteria for GLP-1 therapy, or the contraindication considerations for testosterone replacement is not just compliant. It is the category of content that search engines rank for specific queries and that AI systems draw on when constructing answers to patient questions.

This is not only how AI assistants happen to behave. It is codified in how Google evaluates content. Google’s Search Quality Rater Guidelines classify health information as “Your Money or Your Life” (YMYL): topics that can significantly affect a person’s health, safety, or financial stability. For YMYL pages, Google holds content to the highest standard of what it calls E-E-A-T, which stands for Experience, Expertise, Authoritativeness, and Trust, with Trust as the central member of that set. Google’s own guidance for creators is that health content should be produced by people with the relevant expertise and presented so a reader can tell who is behind it and why they can be trusted. Read that next to an FDA or FTC standard and the overlap is almost exact. The signals Google uses to decide whether a medical page deserves visibility, demonstrated expertise, accurate sourcing, and verifiable trust, are the same signals that make that page defensible to a regulator. Compliance and E-E-A-T are describing the same content from two directions.

The $499.2 million in tracked penalties, including a $150 million single action, represents the cost of the alternative approach. And enforcement is accelerating: 204 actions in the trailing 12 months versus 67 in the prior period.

A clinic cannot simultaneously pursue high-authority positioning in search and AI and rely on claim language that the FTC and FDA have flagged 1,282 times. The claim strategy and the content strategy are mutually exclusive. Clinics that treat compliance as a constraint imposed on marketing are working against themselves. Clinics that treat accurate, physician-reviewed content as the actual marketing product are building the same asset that wins search rankings, earns AI citations, and survives regulatory scrutiny.

---

A Playbook for Competing Where You Can Win

The national platforms named in AI answers are not beatable on their own terms. A regional or single-location clinic will not out-publish Ro, out-spend Hims, or out-rank LaserAway for broad national head terms. That is a factual observation, not a counsel of defeat.

The board has open squares. Here is where to play.

Own your local geography. Buyer-intent searches that include a city, region, or neighborhood sit in a competitive tier that national telehealth platforms are structurally indifferent to. They cannot be the best answer for “hormone therapy clinic in [your city]” the way a local practice with genuine presence and documented local authority can be. Build content that reflects your specific location, your patient population, and your local clinical context.

Target specific, lower-competition queries. Within any vertical, there are question-level queries, protocol-specific queries, and candidacy-specific queries where search volume is lower but competition is thin. A page that thoroughly answers “who is a candidate for peptide therapy” or “what does a GLP-1 consultation involve” is competing for different, more reachable ground than a page chasing “weight loss treatment.”

Publish content that a physician has reviewed and can stand behind. This is the core unit of durable authority. Each page should reflect clinical accuracy, cite the evidence base honestly, and make no claims that outrun what the treating physician would say in an office conversation. That standard is simultaneously what survives an FDA warning letter review and what AI systems treat as citable source material.

Be consistent over time. AI citation patterns and search authority both respond to publishing cadence. A clinic that publishes accurate, specific content monthly across a year accumulates a materially different authority position than one that publishes a burst and stops. This is a slow-build activity, which is also why the incumbents have the lead they have.

Review every public-facing claim against the violation categories in this report. Unsubstantiated efficacy claims account for 1,282 flags in the Atlas. Before any piece of content goes live, a physician should be able to defend every outcome-adjacent statement it contains. If the defense requires evidence the clinic does not have, the claim should not exist in the content.

Treat enforcement as a leading indicator. GLP-1 / Weight Loss drew 82 actions in the trailing 12 months. Pharmacy / Compounding drew 47. Those numbers show where regulators are currently focused, which is also where marketing claim standards are being tested most aggressively. Clinics operating in those verticals should apply proportionally more scrutiny to their claim language, not less.

The clinics that will build durable visibility over the next several quarters are the ones publishing specific, accurate, physician-reviewed content in the local and specific-intent spaces that national platforms ignore, without the claim language that has produced $499.2 million in tracked penalties and 204 enforcement actions in a single year. That is a path that requires discipline and time, but it is a path that national spending cannot close off.

---

Methodology

Enforcement figures are drawn from the Authoritize Atlas, a curated, operator-reviewed library of FDA warning letters and FTC enforcement actions in healthcare and wellness marketing. The corpus spans 1995-06-29 to 2026-06-17 and currently holds 745 published actions across 11 clinical verticals. Entries are identified by keyword-gated monitoring of fda.gov and ftc.gov, so the Atlas is a representative sample of enforcement in these verticals, not a complete census of all FDA or FTC activity. Trend comparisons use trailing-12-month windows anchored to 2026-06-30 to avoid distortion from partial calendar years.

Marketing figures are measured by Authoritize. Search demand and keyword difficulty come from DataForSEO at United States national scope. AI visibility is measured by running buyer-intent questions through ChatGPT, Perplexity, and Google Gemini and recording whether each answer named a specific provider. Provider naming is checked against a curated list per vertical, so the naming share is a floor, not a ceiling. The 132 answers analyzed span 12 clinical verticals.

Both data lanes have limits. The Atlas captures enforcement that reached publication as a warning letter or FTC action; it does not include informal correspondence, consent agreements in process, or actions outside the tracked verticals. Search volume figures reflect national-scope data and do not disaggregate local or long-tail queries. AI answer patterns shift as the underlying models update, so provider naming observed at one point in time may not hold at the next measurement.

For clinics, the combined picture is direct: regulators are more active than at any point in the Atlas history, AI assistants are routing patients toward a small set of national providers in the verticals where they name anyone, and the content practices that earn durable search and AI visibility are identical to the ones that survive regulatory scrutiny. A physician-reviewed content record, built consistently and without overreaching claims, is both the compliance floor and the visibility strategy. Neither the enforcement data nor the AI naming patterns leave much room for a middle path.

Frequently asked questions

How fast is healthcare marketing enforcement growing in 2026? Regulators brought 204 tracked FDA and FTC enforcement actions against healthcare and wellness marketing in the trailing 12 months, up +204.5% from 67 in the prior 12-month period, across 11 clinical verticals tracked in the Authoritize Atlas.

Which healthcare verticals draw the most marketing enforcement? GLP-1 and weight loss led with 82 actions in the trailing 12 months, up +645.5% year over year, followed by pharmacy and compounding with 47 and medical spa and aesthetics with 19.

Do AI assistants recommend specific healthcare providers? Across 132 buyer-intent questions run through ChatGPT, Perplexity, and Google Gemini, the assistants named a specific provider in 30% of answers. The providers named were almost entirely national telehealth and direct-to-consumer brands, not local clinics.

What is the most common healthcare marketing violation? Unsubstantiated efficacy claims, flagged 1,282 times across the Atlas corpus, is the single most common violation category by a wide margin.

Is compliant content better for SEO and AI visibility? Yes. Google classifies health information as Your Money or Your Life (YMYL) and holds it to the highest standard of Experience, Expertise, Authoritativeness, and Trust (E-E-A-T). The accuracy, expertise, and trust signals that earn search and AI visibility are the same ones that make content defensible to the FDA and FTC, so compliance and visibility are the same project.

Where can a local clinic still compete? In local and specific intent: queries tied to a city, a named practitioner, or a specific protocol, where national brands are structurally weak and AI answers frequently name no provider at all.

Sources and further reading

• The enforcement figures come from the Authoritize Atlas, a searchable library of the FDA and FTC actions behind every number in this report.
• Per-vertical editions cover each lane in depth: GLP-1 and weight loss, TRT, medical spa and aesthetics, and peptide therapy.
• Screen your own pages, ads, and emails against the same FDA and FTC patterns with the free Claim Checker.
• Google, Search Quality Rater Guidelines (definitions of YMYL and E-E-A-T).
• Google Search Central, the E-E-A-T update and Creating Helpful, Reliable, People-First Content.
• Primary records: U.S. Food and Drug Administration, Warning Letters; U.S. Federal Trade Commission, Cases and Proceedings.